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1396An unusual risk factor for intrahepatic cholangiocarcinomaTo the Editor:
In the July 2012 issue of the Journal of Hepatology, on the basis of
the meta-analysis of 11 studies, Palmer and Patel [1] reported
that hepatocellular carcinoma (HCC) and intrahepatic cholangio-
carcinoma (ICC) share common risk factors of tumour develop-
ment, such as cirrhosis and chronic viral hepatitis. These
ﬁndings may support the hypothesis that both HCC and ICC are
derived from hepatic progenitor cells, and may explain the path-
ogenesis of combined hepatocellular and cholangiocellular carci-
noma. In the report, extrahepatic cholangiocarcinoma (ECC) was
excluded from the analysis because the clinicopathological fea-
tures of ECC were different from ICC, and the speciﬁc risk factors
for ICC, such as primary sclerosing cholangitis, hepatolithiasis,
and biliary malformations were not within the scope of the
analysis.
At the annual meeting of the Japan Society for Occupational
Medicine held on May 31, 2012, Shinji Kumagai and colleagues
reported ﬁve cases with cholangiocarcinoma among 40 workers
at a printing company in Osaka, Japan [2]. Kumagai and col-
leagues estimated that the incidence of cholangiocarcinoma
among employees of the printing company was about 600 times
higher than the national average, which raised the discussion
about health hazards caused by chemicals. Soon after the report
by Kumagai and colleagues, seven additional employees who
had worked at the printing ﬁrm between 1991 and 2003 were
identiﬁed and presented with cholangiocarcinoma. Seven out of
12 employees with cholangiocarcinoma died at the average age
of 37, being about half the national average age of death from
cholangiocarcinoma [3–5]. On July 11, 2012, the Health, Labor
and Welfare Ministry in Japan stated that a total of 17 cholangi-
ocarcinoma patients with a mortality rate of 47% were identiﬁed
from former and current workers of printing companies across
Japan [6–7]. Of the ﬁrst ﬁve cholangiocarcinomas found at a
printing company, four were ICCs [8], while details about the
remaining cases have not been elucidated. Exposure to large
amounts of volatile organic compounds, such as methylene chlo-
ride (dichloromethane), dichloropropane, and ethylene chloride,
without adequate ventilation is assumed to be responsible for
the development of cholangiocarcinoma in the printing ﬁrm [6–
7]. These organic compounds are solved in cleansers to wash
ink off of printing machines. More than 20 years ago, excess mor-
tality from liver and biliary tract cancer among cellulose ﬁber
production workers in the Unites States was reported [9]. Since
during the cellulose triacetate production process, employeesJournal of Hepatology 20were mainly exposed to the solvent methylene chloride, the asso-
ciation between methylene chloride exposure and development
of liver and biliary tract cancer was suggested. Further, women
from bookprinting and offset printing industries in Denmark
had an odds ratio of developing liver cancer (HCC, ICC, and com-
bined carcinoma) in excess of 10.0 [10]. However, according to a
36.8-year follow-up of 1473 workers, exposed to methylene chlo-
ride on average for 9 years at a concentration of 19 ppm, at a
plant producing cellulose triacetate ﬁlm base, methylene chloride
exposure was not associated with any cancer death [11]. The data
collected at printing companies in Japan and genetic polymor-
phisms of the glutathione pathway involved in the metabolism
of organic compounds suggest that inhalation of organic com-
pounds may be a risk factor for ICC in a population, when expo-
sure exceeds a threshold dose.
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base. Int Arch Occup Environ Health 2011;84:889–897.Controlling gastric variceal bleeding with endoscopically applied
hemostatic powder (HemosprayTM)To the Editor:
Gastric variceal bleeding tends to be more severe (2.9 vs. 4.8
transfusion units per patient) and is associated with a higher mor-
tality (30% vs. 45%) than bleeding from oesophageal varices [1–3].
Failure of endoscopic therapy commonly requires rescue
placement of a transjugular intrahepatic portosystemic shunt
(TIPS) [4], but this option is costly and not always feasible.
HemosprayTM is a novel hemostatic spray recently introduced
for the management of non-variceal upper gastrointestinal bleed-
ing [5].
We describe the ﬁrst case of variceal bleeding refractory to
standard endoscopic therapy, successfully treated with Hemo-
sprayTM, obviating the need for TIPS.
A 79-year-old woman presented to the emergency department
with a 3-day history of melena. Her previous medical history
included idiopathic myeloﬁbrosis with hepatosplenomegaly due
to extramedullary hematopoiesis. This was complicated by portal
hypertension and ascites. Furthermore, she suffered from a severe
hypertension-related pre-existent dilated cardiomyopathy. Previ-
ous upper endoscopy did not show the presence of varices.
At presentation she had a blood pressure of 80/40 mmHg with
a pulse rate of 90 bpm with peripheral cyanosis. On rectal exam-
ination, black stools were noticed. Laboratory test results showed
haemoglobin 4.8 mmol/L, urea 27 mmol/L, creatinine 68 mmol/L,
INR 1.4, and normal transaminases and bilirubin.
In anticipation of a variceal haemorrhage, standard adminis-
tration of an antibiotic (norﬂoxacin 400 mg twice daily) and vaso-
pressor drugs (octreotide) was initiated. Fluid and packed cell
administration was restricted to stabilize vital signs. The patient
was meanwhile transferred to the intensive care unit.
Upper gastrointestinal endoscopy was performed using an
Olympus Q180-1T scope (Olympus, Japan). In the distal esopha-
gus, small varices without bleeding stigmata were seen, but in
the gastric fundus, a profusely bleeding varix of 8 mm (GOV2
[2]) was observed. Next, in three consecutive injections, a total
volume of 2.6 ml HistoAcrylTM with lipiodol was injected. How-
ever, hemostasis could not be achieved and hemodynamic insta-
bility ensued. Rescue treatment with TIPS was considered, but
not pursued given her cardiac condition. Instead of injecting
more HistoAcrylTM, we decided to apply HemosprayTM (Cook
Medical, USA). For this, we sprayed approximately 10 g of
HemosprayTM covering the entire bleeding varix. Persistent
hemostasis was conﬁrmed after 5 min of visual inspection.
The patient received standard post-endoscopic care and went
home. No rebleeding occurred at follow-up at day 7 and 30. We
did not perform a second-look endoscopy given the absence of
signs of rebleeding.
Gastric variceal haemorrhage is an acute life-threatening con-
dition inwhich the endoscopist is challenged to act swift in a tech-
nically demanding retroﬂexed position. Endoscopic managementJournal of Hepatology 201involves single or multiple injection(s) of cyanoacrylate glue into
the varix resulting in the formation of a polymeric plug. Despite its
relative high initial hemostasis rate (87–100%) [1], injection car-
ries distinct risks. First, polymerisation of acrylate beyond the
bleeding site may result in thromboembolic events [1]. Second,
needle obstruction frequently occurs necessitating retrieval. This
means loss of precious time. Third, ulceration of the bleeding site
after injection is commonly seen, and may result in secondary
bleeding [1].
When hemostatic treatment with cyanoacrylate glue fails,
urgent TIPS is not always feasible due to local unavailability,
when the patient condition is too unstable or, as in this case,
when there are clear contraindications such as cardiomyopathy
[6].
HemosprayTM is a novel proprietary hemostatic spray
recently introduced for the management of non-variceal upper
gastrointestinal bleeding. Its safety and efﬁcacy have been
shown in peptic ulcer bleeding [5], as well as in cancer-related
upper GI bleeding [7]. Upon application, this inorganic hemo-
static powder becomes cohesive and adhesive, and forms a sta-
ble mechanical barrier that covers the bleeding site. We report
on the ﬁrst case in literature in which HemosprayTM is success-
fully applied in initially failed endoscopic hemostasis of a vari-
ceal bleeding.
There are few concerns that need to be addressed. Hemo-
sprayTM is applied by a CO2-propelled canister with a positive
outﬂow pressure. Hypothetically, particles may enter the vascu-
lar system and give rise to venous thromboembolisation. How-
ever, the outﬂow pressure at the catheter tip is less than the
known intravariceal venous pressures (often exceeding
15 mmHg) [8] at a distance of 1–2 cm from the mucosa. Also,
data from an ongoing multicentre European initiative on the
use of HemosprayTM for non-variceal upper GI bleeding does
not report incidence of thromboembolism (unpublished data).
Another concern involves the effects of HemosprayTM in coagu-
lation. This is important since most gastric varices occur in cir-
rhotic patients with frequent unbalance of pro- and anti-
coagulatory factors [9]. More studies need to be performed to
elucidate this issue, but preliminary data show only minor
in vitro effects of HemosprayTM on coagulation parameters [10].
In conclusion, Hemospray™ may offer a simple and welcome
alternative in durably controlling bleeding (gastric) varices.
However, we need to await its use in controlled trials to deter-
mine the true added value.
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